Ovarian Cancer

Trametinib monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study.

Michelle M. Boisen, MD, discusses criteria for selecting patients with ovarian cancer for upfront surgery versus neoadjuvant chemotherapy.

Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.

Dana Chase, MD, discusses niraparib as frontline maintenance therapy in ovarian cancer.

Rucaparib was associated with superior outcomes among women with ovarian cancer harboring a non-BRCA homologous recombination repair gene mutation compared with placebo, according to an analysis of specimens collected in the phase III ARIEL3 trial (NCT01968213).

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with paclitaxel in heavily pretreated patients with platinum-resistant ovarian cancer.

Kathleen Moore, MD, discusses the early phase data that led to the development of the phase III FORWARD I/ GOG 3011 trial in ovarian cancer.

Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease.

Elizabeth M. Swisher, MD, discusses how the phase III VELIA/GOG-3005 trial compares with other trials examining up-front maintenance therapy in ovarian cancer.

Veliparib plus chemotherapy extended progression-free survival for BRCA wild-type patients with high-grade serous carcinoma.

The investigational antibody-drug conjugate anetumab ravtansine showed promising antitumor activity in heavily pretreated patients with mesothelin-expressing solid tumors.

An independent panel determined that the investigational agent VB-111 met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without modification.

Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.

In our exclusive interview, Dr. Markman shares the reasons why he dove into the gynecologic cancer space, what mottos he lives by in daily practice, and patient cases that have significantly impacted his career.

Mira Hellmann, MD, discusses the impact of surgery on patients with ovarian cancer.

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the optimal use of PARP inhibitors as frontline maintenance therapy in patients with advanced ovarian cancer.

Ritu Salani, MD, discusses the progression of upfront ovarian cancer treatment.

Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.

Lori Brisbin, discusses using Trapelo, an automated tool to track precision medicine guidelines in various cancers, in patients with ovarian cancer.

Jeannie Chern, MD, discusses challenges with germline molecular testing for patients with ovarian cancer.

The European Medicines Agency has validated a Type II Variation for niraparib as a first-line maintenance treatment for patients with advanced ovarian cancer who have responded to platinum-based chemotherapy, regardless of biomarker status.

The cancer treatment community's ultimate perception of a successfully completed phase III randomized trial depends in large part on how well the trial was conceived and structured. To permit adequate accrual in a timely manner and optimize the chances for a study to achieve success, the question it poses must be relevant to ensure interest by clinical investigators, referring clinicians, and potential research subjects. Further, the initiative must have adequate funding for data collection and analysis, translational laboratory investigations, and other trial components.

Jeannie Chern, MD, a gynecologic oncologist at Moffitt Cancer Center, discusses important germline and somatic mutations to be aware of in ovarian cancer.

Leigha Senter, MS, LGC, discusses ongoing biomarker research efforts in ovarian cancer.

Leigha Senter, MS, LGC, discusses optimal testing methods in ovarian cancer.

Claire Manuszak, BS, discusses the rationale to combine prexasertib (LY2606368) and LY3300054 in patients with high-grade serous ovarian cancer.

Chemotherapy in combination with immunotherapy holds promise in the treatment paradigm for patients with ovarian cancer, Floor Backes, MD, said at the 2020 SGO Winter Meeting.

Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.

Floor J. Backes, MD, discusses the role of PARP inhibitors as treatment of patients with ovarian cancer and her experience with these agents, such as rucaparib.